The pharma supply chain is not a forgiving environment for shortcuts. The processes are complex, the regulatory exposure is real, and the downstream impact of poor data or unclear ownership is significant. Autonomous actions, at any meaningful scale, require you to have already solved for that complexity, not planned to...
How MAHs Reduce EU FMD Alerts (Root Causes, Prevention, and Continuous Improvement)
Reducing alerts is often framed as an execution problem, how quickly can teams investigate and close them? But in practice, the real issue is different. It is not the volume of alerts, but the quality of those alerts.
EAMS Onboarding for MAHs (Access, Teams, Workflows, and Day-to-Day Setup)
The critical detail most teams miss is that AMS access is OBP-based, not MAH-based and as defined by EMVO, OBPs can create users and structure them into teams to control alert visibility by market. The practical implication is that onboarding success depends on how entities, teams, market coverage, and ownership...
EMVO AMS and EAMS Explained for MAHs
The European Medicines Verification System (EMVS) only works at scale when alerts are handled quickly, consistently, and with high-quality data. A single alert at dispensing can trigger quarantine procedures, investigations, and communication with national verification organizations. When this happens across hundreds of SKUs, multiple CMOs, and many European markets, the...
DSCSA in 2026: Full Electronic Interoperability Across Digital Transformation and Daily Operations
This article focuses on DSCSA from an operational execution perspective, how interoperability behaves inside daily warehouse, quality, and supply chain workflows.
